Clinical trial
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the…
NCT00040313 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00040313 |
|---|---|
| Title | Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula |
| Official title | A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial, in Parallel Groups, to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients With Clinically… |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | pegaptanib sodium (Macugen) |
| Enrollment | 0 |
| Start date | Oct 1, 2002 |
| Completion | Feb 1, 2005 |
| First posted | Jun 25, 2002 |
| Last update posted | May 3, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: